Disclosed herein are embodiments of a compound having a Formula I ##STR00001##
or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. Also disclosed are derivative compounds made from the compound of Formula I. Certain derivative compounds have a Formula V-2, or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. ##STR00002## Also disclosed are method for making and using the disclosed compounds. Certain disclosed embodiments are useful for treating and/or preventing certain diseases and/or disorders, including proliferation diseases, such as leukemia.

Disclosed herein are embodiments of a compound having a Formula I ##STR00001##
or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. Also disclosed are derivative compounds made from the compound of Formula I. Certain derivative compounds have a Formula V-2, or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. ##STR00002## Also disclosed are method for making and using the disclosed compounds. Certain disclosed embodiments are useful for treating and/or preventing certain diseases and/or disorders, including proliferation diseases, such as leukemia.

Compounds and pharmaceutically acceptable salts thereof of Formula I are disclosed. Certain compounds and salts of Formula I are active as Top1 and/or Tdp1 inhibitors. The disclosure provides pharmaceutical compositions containing a compound of Formula I as the only active agent, or optionally containing one or more additional active agents. Methods of using compounds of Formula I to treat cancer are provided in this disclosure. The disclosed compounds of Formula I may be used alone to treat cancer, but may also be used in combination with another active agent, such as a Top1 inhibitor, for example, camptothecin or a camptothecin analogue.

Compounds and pharmaceutically acceptable salts thereof of Formula I are disclosed. Certain compounds and salts of Formula I are active as Top1 and/or Tdp1 inhibitors. The disclosure provides pharmaceutical compositions containing a compound of Formula I as the only active agent, or optionally containing one or more additional active agents. Methods of using compounds of Formula I to treat cancer are provided in this disclosure. The disclosed compounds of Formula I may be used alone to treat cancer, but may also be used in combination with another active agent, such as a Top1 inhibitor, for example, camptothecin or a camptothecin analogue.

The present invention relates to an organic light emitting diode comprising: a first electrode; a second electrode facing the first electrode; a hole injecting layer or a hole transport layer, which is interposed between the first electrode and the second electrode; and a light emitting layer, wherein the hole injecting layer or the hole transport layer comprises at least one type of amine compound represented by chemical formula A or chemical formula B, and the chemical formula A and the chemical formula B are the same as those included in the description of the invention.

A heteroacene having the following formula (F) is described. An organic electroluminescence device comprises the heteroacene as a phosphorescent host, a fluorescent host, a hole blocking layer, or an electron transport layer. The heteroacene lowers a driving voltage, or increases a current efficiency or a half-life of the organic electroluminescence device. ##STR00001##

A heteroacene having the following formula (F) is described. An organic electroluminescence device comprises the heteroacene as a phosphorescent host, a fluorescent host, a hole blocking layer, or an electron transport layer. The heteroacene lowers a driving voltage, or increases a current efficiency or a half-life of the organic electroluminescence device. ##STR00001##

The present invention relates to a novel compound and an organic electroluminescent device including the same, and the compound according to the present invention is used in an organic material layer of an organic electroluminescent device, preferably an electron transport layer or a hole blocking layer, and may increase luminous efficiency, driving voltage and lifespan of the organic electroluminescent device.

The present invention relates to a novel compound and an organic electroluminescent device including the same, and the compound according to the present invention is used in an organic material layer of an organic electroluminescent device, preferably an electron transport layer or a hole blocking layer, and may increase luminous efficiency, driving voltage and lifespan of the organic electroluminescent device.

To improve the emission efficiency, the driving voltage and the lifetime of an organic light-emitting device using a delayed fluorescent material. A host material for a delayed fluorescent material, containing a compound represented by the following general formula: R.sup.1 to R.sup.5 each are a substituent not containing a cyano group. n1 to n5 each are 0 to 4, Ar is a monocyclic arylene group or a monocyclic heteroarylene group.

##STR00001##